

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-17 (cancelled).

Claim 18 (currently amended): An isolated polypeptide ~~of claim 17, which is a~~ modified human Factor VIII molecule, the isolated polypeptide being substantially non-immunogenic or less immunogenic than wild-type human Factor VIII, and having essentially the same biological specificity as wild-type human Factor VIII when used *in vivo*, the isolated polypeptide having the amino acid residue sequence of SEQ ID NO: 73, but including at least one specific amino acid residue substitution in SEQ ID NO: 73, wherein at least one of the amino acid residues at the following positions of SEQ ID NO: 73 has been replaced by ~~substituted for~~ a different amino acid; ~~that is present in the amino acid residue sequence of the wild type human Factor VIII:~~ 197, 198, 199, 201, 202, 407, 411, 412, 419, 515, 517, 613, 617, 636, 637, 638, 639, 823, 1011, 1013, 1208, 1209, 1210, 1254, 1255, 1257, 1262, 1264, 1268, 1119, 1120, 1121, 1122, and 1123.

Claim 19 (withdrawn-currently amended). The isolated polypeptide of claim ~~[[17]]~~ 18, wherein the amino acid residue sequence of the polypeptide includes at least one amino acid residue substitution in SEQ ID NO: 73 selected from the group consisting of: M1013K, I1011A, I1011C, I1011D, I1011E, I1011G, I1011H, I1011K, I1011P, I1011Q, I1011R, I1011S, and I1011T.

Claim 20 (currently amended): The isolated polypeptide of claim ~~[[17]]~~ 18, wherein the amino acid residue sequence of the polypeptide includes an ~~at least one~~ amino acid residue substitution in SEQ ID NO: 73 selected from the group consisting of: V823A, V823D, V823E, V823G, V823H, V823N, V823P, V823S, and V823T.

Claim 21 (withdrawn-currently amended). The isolated polypeptide of claim ~~[[17]]~~ 18, wherein the amino acid residue sequence of the polypeptide includes at least on one

amino acid residue substitution in SEQ ID NO: 73 selected from the group consisting of: I1208A, I1208T, I1208N, I1209C, M1210K, and M1210N.

Claim 22 -23 (cancelled).

Claim 24 (currently amended): A pharmaceutical composition comprising a polypeptide of claim [[17]] 18 together with a pharmaceutically acceptable carrier, diluent or excipient.

Claim 25 (previously presented): The isolated polypeptide of claim 20 wherein the amino acid residue substitution in SEQ ID NO: 73 is V823A.

Claim 26 (new): The isolated polypeptide of claim 18, wherein when tested as a whole protein in a biological assay of induced cellular proliferation of human T-cells exhibits a stimulation index (SI) smaller than the parental molecule and smaller than 2 tested in parallel using cells from the same donor wherein said index is taken as the value of cellular proliferation scored following stimulation by the modified Factor VIII protein and divided by the value of cellular proliferation scored in control cells not in receipt of the modified Factor VIII protein and wherein cellular proliferation is measured by any suitable means.

Claim 27 (new): An isolated polypeptide, which is a modified human Factor VIII molecule, the isolated polypeptide being substantially non-immunogenic or less immunogenic than wild-type human Factor VIII, and having essentially the same biological specificity as wild-type human Factor VIII when used *in vivo*, the isolated polypeptide having the amino acid residue sequence of SEQ ID NO: 73, but including at least one specific amino acid residue substitution in SEQ ID NO: 73, wherein said amino acid residue substitution eliminates at least one amino acid sequence identified by *in silico* modeling techniques as a potential T-cell epitope present in wild-type human Factor VIII.

Claim 28 (new): The isolated polypeptide of claim 27, wherein at least one of the amino acid residues at the following positions of SEQ ID NO: 73 has been replaced by a different amino acid: 197, 198, 199, 201, 202, 407, 411, 412, 419, 515, 517, 613, 617, 636, 637, 638, 639, 823, 1011, 1013, 1208, 1209, 1210, 1254, 1255, 1257, 1262, 1264, 1268, 1119, 1120, 1121, 1122, and 1123.

Claim 29 (new): The isolated polypeptide of claim 27, wherein the amino acid residue sequence of the polypeptide includes an amino acid residue substitution in SEQ ID NO: 73 selected from the group consisting of: V823A, V823D, V823E, V823G, V823H, V823N, V823P, V823S, and V823T.

Claim 30 (new): A pharmaceutical composition comprising a polypeptide of claim 27 together with a pharmaceutically acceptable carrier, diluent or excipient.

Claim 31 (new): The isolated polypeptide of claim 29 wherein the amino acid residue substitution in SEQ ID NO: 73 is V823A.